Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...